

# WILLIAM A. WELLS

268 E Broadway #A1402, New York, NY 10002 USA

Phone: +1-917-974-9855

E-mail: [william.a.wells@gmail.com](mailto:william.a.wells@gmail.com)

---

## EDUCATION

**Columbia University**, School of International and Public Affairs

Master of International Affairs (2004-2006).

Concentrations in Economic and Political Development and Public Health.

**University of California, San Francisco**

Ph.D. in Cell Biology (1990-1995). Offered Fulbright scholarship.

**University of Adelaide**, South Australia, Bachelor of Science with Honors (1986-1989).

---

## PUBLIC HEALTH EXPERIENCE

**Senior TB Technical Advisor (2013-)**

*United States Agency for International Development, Washington, DC (USAID)*

Provide strategic and technical guidance globally and to individual countries, with special focus on private provider engagement and operations research. Oversee a TB portfolio of ~\$45m, and provide programmatic and workplanning guidance to USAID missions and projects in countries including Bangladesh, Ethiopia, India, Indonesia, Myanmar, Nigeria and the Philippines. Specific technical guidance topics include: GeneXpert scale-up planning, eTB manager implementation, and short regimen operational research protocol in Bangladesh; community TB and health financing reform in Indonesia; TB investment strategies for Bangladesh and Cambodia USAID missions; and Public-Private Mix (PPM) strategies for Cambodia, Ethiopia, Myanmar, Nigeria and the Philippines. Contributed to international guidance on the End TB strategy, social protection, measurement of catastrophic costs for patients, and integration of TB into national health insurance. Co-chair of Stop TB Partnership's subgroup on PPM. Topic and/or team leader on national TB program reviews in Bangladesh, Indonesia, Myanmar, Philippines, and South Africa.

**Director, Market Access (2008-2013) and Senior Communications Officer (2007-2008)**

*The Global Alliance for TB Drug Development, New York, NY* ([www.tballiance.org](http://www.tballiance.org))

Identified the broader health systems context for TB drug delivery, the place of new TB drugs within that context, and mechanisms to ensure successful adoption, availability, and affordability of new TB drugs.

Drafted strategy for new Market Access Department. Conducted comprehensive market and value analysis for new TB regimens including demand forecasting, cost effectiveness, private sector manufacturing and sales, options for product presentation, patient costs and perceptions, public sector regimen change, and the adoption pathways in the 22 countries with the highest TB burdens; published results in peer-reviewed publications. Managed budgets, contracting, multi-country implementation, and supervision of consultants.

Defined the needs for integrating new regimens and new diagnostics; proposed treatment algorithms; built support for necessary resistance surveillance and product development. Reviewed supply chain management of National TB Programs in Kenya and Nigeria as part of WHO/KNCV program reviews. Co-convened first large-scale meeting on access between product development partnerships (PDPs). Co-Chair of PDP Access Group; initiated cooperative project to analyze the approaches of different PDPs to pricing, manufacturing, financing, pharmacovigilance, and country decision making.

**Consultant, World Health Organization (WHO) (2005-2013)**

*June 2013, Suva, Fiji, and Port Vila, Vanuatu*

Assessed the response to STIs in Fiji and Vanuatu – two Pacific Island Countries with >25% chlamydia prevalence among ante-natal clinic clients. Provided recommendations on management and monitoring.

*August 2012, Phnom Penh, Cambodia*

Evaluated Cambodia's achievement of Universal Access to antiretroviral treatment, and recommended approaches to future strategies, including Treatment as Prevention.

***March and July 2012, Manila, Philippines***

Assessed models for connecting MSM to HIV testing in the Philippines, as a response to a dramatic expansion of the local HIV epidemic. Report endorsed to Minister of Health.

***December 2011 and April 2012, Vientiane, Lao PDR***

After Global Fund R11 cancellation, assessed funding and program options for national HIV response. Worked with 5 NGO and 5 government subrecipients to draft a Global Fund renewal responsive to the findings of an External Program Review and the reduced funding available.

***September 2011, Phnom Penh, Cambodia***

Evaluated the Continuous Quality Improvement initiative being rolled out by Cambodia's HIV program.

***August 2011, Port Moresby, Papua New Guinea***

Outlined options for continued involvement of National Department of Health in Global Fund grant implementation after transfer of Principle Recipient role to other organizations.

***May 2011, Phnom Penh, Cambodia***

Reviewed existing monitoring and evaluation of Cambodia's TB/HIV program; designed a standard operating protocol to strengthen data capture and quality.

***Mar-April 2011, Vientiane and Luang Prabang, Lao PDR***

Reviewed linkage opportunities between HIV, malaria, TB, MNCH and EPI programs in Lao PDR, with a focus on district-level activities.

***October 2010, Phnom Penh and provincial sites, Cambodia***

Evaluated and documented Cambodia's progress in implementing joint TB/HIV activities.

***June-July 2010, Port Moresby, Papua New Guinea***

Lead writer and coordinator of successful \$46 million Round 10 HIV application to the Global Fund, working with Papua New Guinea's CCM and national HIV/AIDS program and 10 NGO subrecipients.

***Jan-Feb 2010, Port Moresby, Papua New Guinea***

Coordinated development of a successful Continuity of Services (CoS) application to the Global Fund.

***December 2008, Manila, Philippines***

Evaluated WHO's regional involvement with Global Fund, resulting in published policy document.

***May-June 2007, Manila, Philippines, and Guilin, China***

Drafted Asia-Pacific Operational Framework for Linking STI/HIV Services with Reproductive, Maternal and Child Health. Moderated regional consultation and generated final, published guidance.

***Nov 2005-Feb 2006, New York, USA, and Phnom Penh and provincial sites, Cambodia***

Assessed the positive and negative spillover effects of HIV programs (specifically, the Continuum of Care (CoC)) on the rest of the healthcare system in Cambodia.

***United Nations Children's Fund (UNICEF), Cambodia***

***Mar-May 2007; Consultancy, Phnom Penh, Cambodia***

Coordinated development of the orphans and vulnerable children (OVC) subcomponent of Cambodia's application for Round 7 of the Global Fund. This included subrecipient selection, ensuring a unified programmatic focus, budgeting and M&E, writing the proposal text, and collaborating with the Ministry of Social Affairs to identify their priorities and develop their proposal. The grant was fully funded.

***Foundation for AIDS Research (amfAR)***

***April-June 2006; Consultancy, New York, USA***

Wrote 30-page advocacy paper explaining need for MSM prevention programs in Asia. CD copies were distributed to all registrants at the 2006 Toronto AIDS meeting.

***Mar-Aug 2005; Consultancy, New York, USA and Kobe, Japan***

Wrote successful grant application for the International Epidemiologic Database to Evaluate AIDS, including a 35 page research plan and multi-million dollar budget.

*United Nations Population Fund (UNFPA), Sudan*

*Oct 2005-Apr 2006; Group Consultancy, New York, USA, and Khartoum, Sudan*

Population and Reproductive Health Assessment for UN country team.

## EDITORIAL EXPERIENCE

**News Director (2006-2007), Senior News Editor (2004-2006) and News Editor (2001-2004)**

*Rockefeller University Press, New York, NY* (www.rockefeller.edu/rupress; www.jcb.org; www.jem.org)

Created news sections in two major scientific journals, then wrote, commissioned and edited for these news sections. This involved hiring and directly supervising three staff writers, multiple freelance writers, and two designers, and coordinating production with ~20 additional editorial staff.

Directed redesigns of both journals and oversaw public policy for a University Press. Invited to speak on science policy at Harvard Medical School and other locations, and to teach science writing courses at University of Pennsylvania, Harvard Medical School, Rockefeller University, and Beijing University (course later modified for CARE, WHO and FHI in Cambodia).

**Freelance Scientific Writer and Editor (1996-2001)**

Wrote hundreds of feature and news articles for publications including *New Scientist* and *Forbes*.

Wrote educational materials (distributed nationally) for schools and US congress.

Sole staff writer for major US National Academy of Sciences report on “Scientific and Medical Aspects of Human Reproductive Cloning”.

**In-house Editor (1995-1996)**

*Current Biology Ltd.*, San Francisco, CA.

Reached editorial decisions on accepting research manuscripts.

## PEER-REVIEWED PUBLICATIONS

Peer-reviewed publications in global public health include the following:

**Wells WA**.\* Onions and prevalence surveys: how to analyze and quantify tuberculosis case-finding gaps. *Int J Tuberc Lung Dis*. 2017. 21:1101-1113.

Gomez GB, Dowdy DW, Bastos ML, Zwerling A, Sweeney S, Foster N, Trajman A, Islam MA, Kapiga S, Sinanovic E, Knight GM, White RG, **Wells WA**, Cobelens FG, Vassall A. Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis. *BMC Infect Dis*. 2016. 16:726.

Uplekar M, Atre S, **Wells WA**, Weil D, Lopez R, Migliori GB, Raviglione M. Mandatory tuberculosis case notification in high tuberculosis-incidence countries: policy and practice. *Eur Respir J*. 2016. 48:1571-1581.

Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Husain A, Hussain A, Ismail N, Kamal M, Mansjö M, Mvusi L, Niemann S, Omar SV, Qadeer E, Rigouts L, Ruesch-Gerdes S, Schito M, Seyfaddinova M, Skrahina A, Tahseen S, **Wells WA**, Mukadi YD, Kimerling M, Floyd K, Weyer K, Raviglione MC. Population-based resistance of *Mycobacterium tuberculosis* isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. *Lancet Infect Dis*. 2016. 16:1185-92.

Trajman A, Bastos ML, Belo M, Calaça J, Gaspar J, dos Santos AM, dos Santos CM, Brito RT, **Wells WA**, Cobelens FG, Vassall A, Gomez GB. Shortened first-line TB treatment in Brazil: potential cost savings for patients and health services. *BMC Health Services Research*. 2016. 16:27. doi:10.1186/s12913-016-1269-x.

Knight GM, Gomez GB, Dodd P, Dowdy D, Zwerling A, **Wells WA**, Cobelens F, Vassall A, White RW. The impact and cost-effectiveness of a four-month regimen for first-line treatment of active tuberculosis in South Africa. *PLoS ONE*. 2015. 10(12): e0145796. doi:10.1371/journal.pone.0145796.

- Wells WA,\*** Uplekar M, Pai M. Achieving systemic and scalable private sector engagement in TB care and prevention in Asia. *PLoS Med.* 2015. 12(6): e1001842. doi:10.1371/journal.pmed.1001842.
- Denkinger CM, Dolinger D, Schito M, **Wells WA**, Cobelens F, Pai M, Zignol M, Cirillo DM, Alland D, Casenghi M, Gallarda J, Boehme CC, Perkins MD. Target product profile of a molecular drug-susceptibility test for use in microscopy centers. *J Infect Dis.* 2015. 211(suppl 2):S29-S38.
- Gospodarevskaya E, Tulloch O, Bunga C, Ferdous S, Jonas A, Islam S, Rahman M, Hussain MA, Haque MN, Egwaga S, Gardiner E, PrayGod G, Islam MA, Mann GH, **Wells WA**, Squire SB. Patient costs during tuberculosis treatment in Bangladesh and Tanzania: the potential of shorter regimens. *Int J Tuberc Lung Dis.* 2014. 18:810-7.
- Wells WA**, et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. *Lancet Infect Dis.* 2013. 13:449-58.
- Eang MT, Vun MC, Eam KK, Sovannarith S, Sopheap S, Bora N, Yadav R, Fujita M, Tomas B, Ghidinelli M, van Maaren P, **Wells WA.\*** The multi-step process of building TB/HIV collaboration in Cambodia. *Health Res Policy Syst.* 2012. 10:34.
- Wells WA,\*** Ge CF, Patel N, Oh T, Gardiner E, Kimerling ME. Size and usage patterns of private TB drug markets in the high burden countries. *PLoS ONE.* 2011. 6:e18964. Findings from this study were picked up by the Financial Times, the Telegraph (Calcutta), the Times of India, *Nature Medicine*, Aidsmap, and Radio Australia.
- Wells WA,\*** Konduri N, Chen C, Lee D, Ignatius HR, Gardiner E, Schwalbe NR. Implications of the current tuberculosis treatment landscape for future regimen change. *Int J Tuberc Lung Dis.* 2011. 15:746-53.
- Wells WA,\*** Brooks A. Adoption of new health products in low and middle income settings: How product development partnerships can support country decision making. *Health Res Policy Syst.* 2011. 9:15.
- Wells WA,\*** Konduri N, Chen C, Lee D, Ignatius HR, Gardiner E, Schwalbe NR. Tuberculosis regimen change in high-burden countries. *Int J Tuberc Lung Dis.* 2010. 14:1538-47.
- Brooks AD,\* **Wells WA**, McLean TD, Khanna R, Coghlan R, Mertenskoetter T, Privor-Dumm LA, Krattiger A, Mahoney RT. Ensuring that developing countries have access to new healthcare products: The role of product development partnerships. *Innov Strat Today.* 2010. 3:1-5.
- Schwalbe NR, **Wells WA,\*** Geaneotes AP, Forcellina A, Lee MG, Dicola L, Ignatius HR, Walker CL, Raafat T, Patel N. Estimating the market for tuberculosis drugs in industrialized and developing nations. *Int J Tuberc Lung Dis.* 2008. 12:1173-81.

\*Corresponding author.